NEW YORK, March 28, 2017 /PRNewswire/ --
This morning's research on Stock-Callers.com draws investors' attentionto these four stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN). These companies operate in the Generic Drugs space which
On Monday, shares in Parsippany, New Jersey-based The Medicines Co. recorded a trading volume of 903,995 shares. The stock ended the session 0.43% higher at $50.91. The Company's shares have surged 47.27% over the previous three months and 50.00% on an YTD basis. The stock is trading 9.31% above its 50-day moving average and 30.80% above its 200-day moving average. Moreover, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have a Relative Strength Index (RSI) of 55.31.
On February 28th, 2017, Medicines Co. announced its financial results for Q4 2016 and full year ended December 31st, 2016. For Q4, worldwide net revenue was $25.2 million, and net loss from continuing operations was $124.4 million. For full year 2016, worldwide net revenue was $167.8 million, and net loss from continuing operations was $119.4 million. The free research report on MDCO is available at:
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s stock closed the day 0.18% higher at $17.17, with a total trading volume of 984,156 shares. The Company's shares have advanced 4.57% in the past month, 11.71% in the previous three months, and 12.30% since the start of this year. The stock is trading 5.33% and 15.53% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 56.06. The complimentary report on IRWD can be downloaded at: http://stock-callers.com/registration/?symbol=IRWD
Shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. recorded a trading volume of 575,439 shares. The stock ended yesterday's trading session 1.39% higher at $47.55. The Company's shares have advanced 9.44% in the past month, 50.47% in the last three months, and 47.21% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.88% and 23.66%, respectively. Furthermore, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 55.88.
On March 16th, 2017, Pacira Pharmaceuticals and Trinity Health announced that they will collaborate to develop an alternative approach to opioids for pain management. In their collaboration, the duo will work to improve the overall patient-recovery experience and decrease the threat of long-term opioid risks, which include misuse, abuse, and addiction.
On March 23rd, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $59 a share to $54 a share. Visit us today and download our complete research report on PCRX for free at:http://stock-callers.com/registration/?symbol=PCRX
Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock finished Monday's session 2.84% higher at $30.80. A total volume of 904,383 shares was traded, which was above their three months average volume of 543,970 shares. The Company's shares have advanced 21.74% in the last one month, 23.69% over the previous three months, and 21.98% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 16.54% and 32.07%, respectively. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 63.20.
On March 07th, 2017, Supernus Pharmaceuticals announced that it has entered into a binding term sheet with Actavis Laboratories, Florida, Inc. et al. involving the ongoing patent litigation regarding Actavis' Abbreviated New Drug Application seeking approval to market generic versions of Supernus Pharma's Trokendi XR® capsules. The binding term sheet permits Actavis to begin selling a generic version of Trokendi XR® on January 01st, 2023 or earlier under certain circumstances. Get free access to your technical report on SUPN at:http://stock-callers.com/registration/?symbol=SUPN
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://stock-callers.com/legal-disclaimer/
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All